TTM
$0.00
YoY change
—
5Y CAGR
-100.0%
Peak year (2014)
$7.92M
Cumulative gross profit
−$12.52M
Gross Profit history chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: $0.00
Gross Profit growth chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: -100.0%
Gross Profit history table for SELLAS Life Sciences Group (SLS) from 2006 to 2025
| 2025 | $0.00 | — | $0.00 | ||
| 2024 | $0.00 | — | $0.00 | ||
| 2023 | $0.00 | -100.0% | −$900.00K | ||
| 2022 | $900.00K | -87.8% | −$6.50M | ||
| 2021 | $7.40M | +289.5% | +$5.50M | ||
| 2020 | $1.90M | — | +$1.90M | ||
| 2019 | $0.00 | — | $0.00 | ||
| 2018 | $0.00 | — | $0.00 | ||
| 2017 | $0.00 | -100.0% | +$3.00K | ||
| 2016 | −$3.00K | -99.2% | +$352.00K | ||
| 2015 | −$355.00K | -104.5% | −$8.27M | ||
| 2014 | $7.92M | +302.4% | +$5.95M | ||
| 2013 | $1.97M | -4114.3% | +$2.02M | ||
| 2012 | −$49.00K | -99.8% | +$20.74M | ||
| 2011 | −$20.79M | — | −$20.79M | ||
| 2010 | $0.00 | — | $0.00 | ||
| 2009 | $0.00 | — | $0.00 | ||
| 2008 | $0.00 | -100.0% | +$11.41M | ||
| 2007 | −$11.41M | — | −$11.41M | ||
| 2006 | $0.00 | — | — |
- 2025$0.00—
- 2024$0.00—
- 2023$0.00-100.0%
- 2022$900.00K-87.8%
- 2021$7.40M+289.5%
- 2020$1.90M—
- 2019$0.00—
- 2018$0.00—
- 2017$0.00-100.0%
- 2016−$3.00K-99.2%
- 2015−$355.00K-104.5%
- 2014$7.92M+302.4%
- 2013$1.97M-4114.3%
- 2012−$49.00K-99.8%
- 2011−$20.79M—
- 2010$0.00—
- 2009$0.00—
- 2008$0.00-100.0%
- 2007−$11.41M—
- 2006$0.00—
Gross Profit values are taken from SELLAS Life Sciences Group's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Gross Profit at SELLAS Life Sciences Group (SLS)
According to SELLAS Life Sciences Group's latest reported financial statements, the company's current gross profit (TTM) is $0.00. Gross profit equals revenue minus the cost of goods sold (COGS) — what remains from sales after the direct cost of producing the product or service. It does not yet subtract operating expenses, interest, or taxes (see operating income and net income for those steps). Higher gross profit (and gross margin) generally signals pricing power and production efficiency.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual gross profit for SELLAS Life Sciences Group (SLS) came in at $0.00.
Across 2020–2025 (5 years), SELLAS Life Sciences Group gross profit produced a CAGR of -100.0% – with a net decline across the window.
SELLAS Life Sciences Group gross profit peaked at $7.92M in 2014; the latest annual figure is $0.00 in 2025 (100.0% below peak).
2014 marks the peak gross profit at $7.92M, with the historical low of −$20.79M recorded in 2011.
SELLAS Life Sciences Group Gross Profit by Year
SELLAS Life Sciences Group Gross Profit 2025: $0.00
SELLAS Life Sciences Group gross profit in 2025 was $0.00.
SELLAS Life Sciences Group Gross Profit 2024: $0.00
SELLAS Life Sciences Group gross profit in 2024 was $0.00.
SELLAS Life Sciences Group Gross Profit 2023: $0.00
SELLAS Life Sciences Group posted gross profit of $0.00 in 2023, plunged 100.0% below 2022.
SELLAS Life Sciences Group Gross Profit 2022: $900.00K
In 2022, SELLAS Life Sciences Group reported gross profit of $900.00K, plunged 87.8% below 2021.
SELLAS Life Sciences Group Gross Profit 2021: $7.40M
SELLAS Life Sciences Group gross profit in 2021 was $7.40M.
See more financial history for SELLAS Life Sciences Group (SLS).
Sector peers by Gross Profit
Healthcare peers of SELLAS Life Sciences Group (SLS), ranked by their latest gross profit
| $82.92B | |
| $68.56B | |
| $54.62B | |
| $48.11B | |
| $46.73B | |
| $42.96B | |
| $39.01B | |
| $26.01B |
- $82.92B
- $68.56B
- $54.62B
- $48.11B
- $46.73B
- $42.96B
- $39.01B
- $26.01B
Frequently asked questions
SELLAS Life Sciences Group (SLS) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation